Quick Answer
Tvardi Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $20.73 million for the year ending 2025.
- Tvardi Therapeutics, Inc. showed a decrease of -34.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Tvardi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), Tvardi Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 406.1%.
- Historical annual values: Fiscal year 2025: $20.73 million | Fiscal year 2024: $31.61 million | Fiscal year 2023: $51.78 million | Fiscal year 2022: $63.74 million | Fiscal year 2021: $13.45 million | Fiscal year 2020: $31.68 million | Fiscal year 2019: $18.31 million | Fiscal year 2018: $15.08 million | Fiscal year 2017: $9.39 million | Fiscal year 2016: $12.09 million | Fiscal year 2015: $15.10 million | Fiscal year 2014: $52.66 million | Fiscal year 2013: $12.36 million | Fiscal year 2012: $1.12 million | Fiscal year 2011: $4.10 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: